Croma-Pharma boosts market share & cataract portfolio
Austrian pharmaceutical firm Croma-Pharma has acquired two companies, thus strengthening its cataract surgery portfolio and, according to the firm, moving it into the top five list of companies operating in the European ophthalmic market.
Austrian pharmaceutical firm Croma-Pharma has acquired two companies, thus strengthening its cataract surgery portfolio and, according to the firm, moving it into the top five list of companies operating in the European ophthalmic market.
Specifically, the firm has now completed the acquisitions of Cornéal Laboratoir and Xcelens.
Cornéal has a strong line of products for anterior and posterior surgery, such as viscolelastic fluids, IOLs and medical devices. Xcelens, despite only being founded in 2003, also has a reputation as a leading provider in the cataract surgery field, with its main interest lying in export.
These acquisitions have now made Croma-Pharma a one-stop provider of cataract surgery products.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
